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 Infusions of cholesterol-free reconstituted HDL (rHDL) 
particles have been shown to rapidly reverse atherosclero-
sis in a wide variety of animal models and in clinical trials 
of acute coronary syndrome patients ( 1–5 ). While a signifi -
cant emphasis has been placed on investigating the HDL 
protein component, i.e., ApoA-I, ApoA-I mutants, and mi-
metic peptides, the importance of HDL phospholipid 
(PL) composition has not been systematically investigated. 
Lipid represents 50–80% of the total HDL mass and is 
known to affect particle stability in vivo, cholesterol effl ux 
from macrophages, the ability to interact with LCAT, and 
cholesterol elimination ( 6–11 ). Lipid composition also 
largely defi nes the size, net charge, and rigidity of the 
rHDL particles; all are important factors in the pharmaco-
kinetic and pharmacodynamic properties of rHDL. The 
investigation of the effects of lipid composition on the re-
sulting rHDL properties in vitro and in vivo is the focus of 
this article. By better defi ning the lipid effect of rHDL, we 
hope to be able to favorably alter the potency and safety of 
rHDL, and ultimately advance clinical translation of these 
potentially life-changing nanomedicines. 
 The PL composition of endogenous HDL contains 
phosphatidylcholines (PCs), SM, and small amounts of ly-
sophosphatidylcholine (LPC), phosphatidylethanolamine, 
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9-fl uorenylmethyl carbamate protection chemistry and was puri-
fi ed with reverse phase chromatography. Peptide purity was 
>95%, as determined by HPLC. Egg SM and POPC were pur-
chased from Avanti Polar Lipids (Alabaster, AL) and Nippon Oil 
and Fat (Osaka, Japan). All other materials were obtained from 
commercial sources. 
 Preparation and characterization of 5A PL complexes 
 HDL-like 5A-POPC and 5A-SM complexes were prepared by a 
co-lyophilization procedure ( 25, 26 ). Peptide and PLs were dis-
solved in glacial acetic acid and mixed at 1:1.25 w/w ratio (ap-
proximately 1:7 molar ratio) and lyophilized. The powder was 
hydrated with bicarbonate buffered saline and cycled between 
50°C and room temperature to facilitate 5A-lipid binding. The 
resulting HDL complexes were analyzed by gel permeation chro-
matography, with UV detection at 220 nm, using a Tosoh TSK gel 
G3000SWxl column (Tosoh Bioscience , King of Prussia, PA). 
The HDL hydrodynamic diameters were determined by dynamic 
light scattering (DLS), using a Zetasizer Nano ZSP (Malvern In-
struments, Westborough, MA). The volume intensity average val-
ues were reported. The   -helical contents of free and lipid bound 
5A peptide were determined by Jasco J715 (Jasco, Easton, MD) 
circular dichroism spectropolarimeter. Samples at 0.1 mg/ml 
concentration were loaded into a quartz cuvette (d = 0.2 cm path 
length), and circular dichroism (CD) spectra from 185 to 240 nm 
were recorded at 24°C. Data were normalized by calculating the 
mean residue ellipticity (  ). 
 Transmission electron microscopy (TEM) images were ob-
tained using a JEM 1200EX electron microscope (JEOL, USA) 
equipped with an AMT XR-60 digital camera (Advanced Micros-
copy Techniques Corp.). Images were acquired at magnifi cations 
from 60,000- to 150,000-fold. HDL samples, 3   l aliquots, were 
deposited on carbon fi lm-coated 400 mesh copper grids (Elec-
tron Microscopy Sciences) and dried for 1 min. The samples 
were negatively stained with 1% uranyl acetate solution; the grids 
were blotted with tissue and dried before TEM observation. 
 Cholesterol effl ux assay in vitro 
 Cholesterol effl ux studies were performed as described previ-
ously ( 25, 26 ). Briefl y, baby hamster kidney (BHK)-mock and 
BHK stably transfected cells with human ABCA1 cDNA, ABCG1 
cDNA, and SR-BI cDNA were labeled for 24 h with 1   Ci/ml of 
 3 H-cholesterol in minimum essential medium plus 10% fetal calf 
serum . Transporters were induced with 10 nM mifepristone in 
DMEM, containing 0.2 mg/ml of fatty acid-free BSA for 18 h. Fol-
lowing induction of the transporters, the cells were washed and 
rHDLs or 5A were added at 0.1, 2.5, 5, 10, 20, and 40 mM peptide 
concentrations in DMEM-BSA-mifepristone media. After 18 h 
of incubation, media were collected and fi ltered using a 24-well, 
25-  m pore size plate fi lter (Whatman-GE Healthcare, Pittsburg, 
PA) and cells were lysed in 0.4 ml of 0.1% SDS and 0.1 N NaOH. 
Radioactive counts in media and cell fractions were measured by 
liquid scintillation counting, and percent cholesterol effl uxed 
was calculated by dividing the media count by the sum of the 
media and cell counts. 
 Plasma HDL remodeling 
 Remodeling of rHDL in plasma was assessed by addition of 
50   l of 5, 1, or 0.5 mg/ml of 5A-SM or 5A-POPC to 450   l of pooled 
human plasma. The fi nal concentrations of peptide in plasma 
were 0.5, 0.1, and 0.05 mg/ml, respectively. Plasma incubation 
with the same volume of PBS was used as a control. Samples were 
incubated at 37°C for 1 h under shaking at 300 rpm prior to elec-
trophoresis. The various subclasses of HDL were separated by 
phosphatidylinositol, and other lipids ( 12–14 ). The differ-
ences in lipid composition of various subclasses of HDL 
and how they relate to disease have been gaining attention 
in recent years ( 12–14 ). However, a single source of lipid 
is used for preparation of rHDL for most academic re-
search and clinical development ( 2–5, 15–18 ). The fi rst 
lipid used to prepare rHDLs for human testing was soy-
bean PC (soyPC), because this lipid was shown to be safe 
for parenteral nutrition products and is readily commer-
cially available in infusion grade ( 18 ). Thus recombi-
nant proApoA-I (a product of UCB Pharma, Anderlecht, 
Belgium) and blood purifi ed ApoA-I (CSL-111, a product 
of CSL Behring, Australia) were reconstituted with soyPC 
( 15, 16 ). As a greater variety of infusion grade chemically 
defi ned lipids became commercially available, the PL com-
position used in the preparation of rHDL diversifi ed. A 
POPC was fi rst used in ETC-216 (rApoA-I-Milano), and then 
a mixture of 1,2-dipalmitoyl- sn -glycero-3-phosphocholine 
(DPPC) and SM was used for ETC-642, a peptide-based 
rHDL ( 17, 19 ). Most recently, SM was used in CER-001, 
another newly developed rApoA-I-based rHDL ( 20 ). Both 
SM and saturated fatty acid-containing lipids like DPPC 
have superior cholesterol binding capacity relative to un-
saturated POPC and soyPC ( 21, 22 ). In fact, SM has the 
strongest cholesterol binding affi nity governed by Van 
der Waals’ interaction due to the mismatched fatty acid 
lengths ( 21 ). SM is also known to form lipid-raft sections 
in cellular membrane that contain up to 50% cholesterol 
( 23 ). The rHDLs made from saturated lipids exhibited 
greater cholesterol effl ux from macrophages in vitro ( 8, 9 ) 
and cholesterol mobilization in vivo ( 24 ). However, un-
saturation enhances rHDL interaction with LCAT ( 11 ), 
whereas SM was reported to inhibit cholesterol esterifi ca-
tion in vitro ( 6 ). 
 In this study, we hypothesized that the higher choles-
terol binding affi nity of SM relative to POPC would trans-
late into greater cholesterol effl ux both in vitro and in 
vivo. The ApoA-I mimetic, 5A, a 37-amino acid-long bi-
helical peptide ( 25 ), was used to form SM- and POPC-
based HDL particles. The 5A-based HDL has several similar 
features to HDL prepared from the full-length ApoA-I, 
namely, an equivalent ability to promote cholesterol effl ux 
in vitro and in vivo ( 25, 26 ), and similar abilities in re-
ducing the development of atherosclerosis ( 26 ) and sup-
pressing infl ammation ( 27 ). In this study, differences in 
cholesterol effl ux and infl ammatory cytokine release inhi-
bition were examined for 5A-POPC and 5A-SM. In addi-
tion, the ability of the two different lipid preparations of 
5A were tested in vivo on their ability to mobilize and es-
terify cholesterol and on their effect in atherosclerosis 
development. 
 MATERIALS AND METHODS 
 Materials 
 5A (DWLKAFYDKVAEKLKEAFPDWAKAAYDKAAEKAKEAA) 
was synthesized by GenScript (Piscataway, NJ), using solid-phase 
 at BIBLIO
TECA ALBERTO
 M
ALLIANI, on M
arch 30, 2016
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2015/06/27/jlr.M060285.DC1
Supplemental Material can be found at:
Lipid composition of rHDL affects its pharmacological properties 1729
 Distribution of mobilized cholesterol in lipoproteins 
 The rat sera samples were analyzed to assess cholesterol distri-
bution between VLDL, LDL, and HDL lipoprotein fractions. 
Separation of lipoproteins was performed on a Waters HPLC sys-
tem equipped with a Superose 6 10/300 GL column (GE Health-
care, Piscataway, NJ) and a fraction collector. Rat sera prior to 
dosing and 30 min postinjection of 100 mg/ml 5A-SM and 5A-
POPC were analyzed. Fifty microliter aliquots were injected and 
eluted with saline solution at 1 ml/min. Elution fractions (0.5 ml) 
were collected with a Waters fraction collector and analyzed for 
TC by an enzymatic kit. The levels of cholesterol were plotted as 
a function of fraction time. 
 Anti-atherosclerotic activity in ApoE   /   mice 
 Eight-week-old male ApoE knockout (ApoE   /   ) mice were fed 
a high-fat high-cholesterol diet (21% fat, 34% sucrose, and 0.2% 
cholesterol; Harlan, T.D. 88137) for 14 weeks to develop athero-
sclerotic lesions, at which point mice were either euthanized 
(baseline) or switched to a chow diet for 6 weeks. Coincident 
with the switch to chow diet, mice were randomized into three 
groups and received an intraperitoneal injection three times a 
week (Monday, Wednesday, and Friday) of either 5A-POPC or 
5A-SM at 50 mg/kg dose or an equivalent volume (200   l) of PBS 
control for 6 weeks. The left ventricle of the heart was perfused 
with PBS, followed by a fi xative solution (4% paraformaldehyde 
in PBS). The aorta was dissected from its origin in the heart to 
the ileal bifurcation and stained with oil red O solution, then 
destained for 30 min in 70% ethanol, and fi nally washed in water. 
After removal of any remaining adventitial fat, aortas were cut 
longitudinally and pinned fl at onto a black-wax plate. The per-
centage of the plaque area stained by oil red O with respect to 
the total luminal surface area was quantifi ed with ImageJ analysis 
software. To quantify the extent of the atherosclerotic lesions in 
the aortic root, the atherosclerotic lesions in the aortic sinus re-
gion were examined at three locations, each separated by 80   m. 
The largest plaque of the three valve leafl ets was adopted for 
morphological analysis. The lipid-burden plaque areas at the 
aortic sinus were determined by oil red O staining. 
 RESULTS 
 Preparation and characterization of rHDLs 
 rHDL particles were prepared by combining 5A peptide 
with either SM or POPC, using a co-lyophilization proce-
dure. Preliminary studies were performed to determine 
the optimal weight ratio of peptide to PLs for formation of 
homogeneous rHDL complexes. The ratio of 1:1.25 wt/wt 
or 1:7 mole:mole of peptide to PL was selected . Higher 
ratios of lipid to peptide resulted in greater rHDL hetero-
geneity and the presence of liposome impurities. Lower 
amounts of lipid resulted in the presence of some lipid-
free peptide. The optimum weight ratio of peptide to PL 
ranged between 1:1.25 and 1:1.5 and resulted in homoge-
nous rHDL particle size distribution. The 1:1.25 ratio was 
chosen as the preferred formulation. 
 The analysis of the purity of rHDL complexes was per-
formed by gel permeation chromatography, shown in supple-
mentary Fig. 1. The results indicate formation of rHDL 
(elutes at 7 min) and a presence of PL-unbound or free 5A 
peptide (12 min retention time ). The POPC-HDL contained 
size and charge by 1D or 2D native page gel electrophoresis and 
visualized by Western blot using anti-ApoA-I antibody. 
 To visualize native HDL particles separated by size, samples 
were subjected to electrophoresis using 10-well Tris-borate-EDTA 
(TBE) gradient (3–25%) acrylamide mini-gels (Jule, Inc., Milford, 
CT) ( 28 ). For each well, 5   l of rat and human plasma incubated 
with or without rHDL was mixed with 5   l of 2× TBE sample buf-
fer and 6   l of the resulting mixtures were loaded per well . Gels 
were run at 200 V until the sample dye was 2.5 cm away from the 
bottom of the gel. Proteins were visualized by Western blot by 
transfer onto polyvinylidene difl uoride membrane and incubation 
overnight with anti-human and anti-rat ApoA-I-HRP-conjugated 
antibody (Meridian Life Science, Memphis, TN). Antibody solu-
tion was prepared by mixing 3   l of antibody with 40 ml of anti-
body dilution buffer. Images were acquired on an Alpha Innotech 
Chemi Imager 5500 and the Alpha Ease FC program was used for 
spot densitometry. 
 To visualize native HDL particles separated by charge and size, 
samples were subjected to native-native 2D gel electrophoresis 
( 29 ). For each sample, 2   l plasma incubated with rHDLs or PBS 
control, 4   l sample buffer, and 8   l Tris tricine buffer were com-
bined. A 10.0   l aliquot was added per well of the fi rst-dimension 
gel (0.7% agarose), followed by second-dimension electrophore-
sis on a 3–25% acrylamide gradient TBE mini-gels (Jule, Inc.). 
The Western blot analysis and visualization was performed as de-
scribed above. The classifi cation of various HDL subclasses was 
performed in accordance with Asztalos, Tani, and Schaefer ( 30 ). 
 Inhibition of cytokine release testing 
 Inhibition of cytokine release from murine peritoneal mac-
rophages following lipopolysaccharide (LPS) stimulation was 
determined for 5A-SM, 5A-POPC, free 5A peptide, and PBS con-
trols. Mouse peritoneal lavage was performed with 5 ml of sterile 
PBS. Peritoneal macrophages were washed, collected by centrifu-
gation, and reconstituted in DMEM containing 10% FBS. Cells 
were plated, attached, washed twice with PBS, stripped by trypsin, 
and counted. Macrophages were seeded at 100,000 cells per well 
and incubated for 2 h, followed by addition of rHDLs at 0.01, 0.1, 
and 1 mg/ml peptide concentrations for 18 h. The cells were 
washed again, treated with 1   g/ml of LPS for 2 h, washed again, 
and incubated for 6 h. The media were collected and the levels of 
TNF-  were determined using BioLegend ELISA kits (San Diego, 
CA) as per the manufacturer’s instructions. 
 Determination of cytokine release inhibition in whole human 
blood was performed by pretreating heparinized human blood for 
1 h with 5A-SM, 5A-POPC, and free 5A peptide controls at 0, 0.01, 
and 0.1 mg/ml peptide concentrations. Cytokine release was stim-
ulated by addition of 1   g/ml of phytohemaglutinin-M (PHA) fol-
lowed by an overnight incubation. The cells were collected by 
centrifugation and the levels of IL-1  , IL-6, and TNF-  were mea-
sured by Human ProInfl ammatory-4 I tissue culture kit using 
SECTOR ® Imager 2400 from Meso Scale Discovery (Rockville, MD). 
 Cholesterol mobilization and esterifi cation in vivo 
 Sprague-Dawley rats (8 weeks old) were purchased form Charles 
River Breeding Laboratories (Portage, MI) and were fed a regular 
rodent chow diet. To determine the dose response, 5A-SM and 5A-
POPC were administered intravenously via the tail veil at 30 and 
100 mg/kg doses based on the peptide amount. The plasma sam-
ples were collected predose and at 0.5, 1, 2, 4, 6, 8, 12, and 24 h 
after the infusion, and the levels of plasma PLs, total cholesterol 
(TC), and unesterifi ed or free cholesterol (FC) were determined 
by enzymatic analysis using commercially available kits (Wako 
Chemicals, Richmond, VA). Cholesterol ester (CE) level was calcu-
lated as a difference between TC and FC levels at each time point. 
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to also promote cholesterol effl ux to lipid-free 5A. Recon-
stituting 5A with either POPC or SM did not interfere with 
this process; in fact, both 5A-POPC and 5A-SM showed 
higher cholesterol effl ux than lipid-free 5A and were simi-
lar to each other. In contrast, ABCG1 and SR-BI are known 
to primarily promote cholesterol effl ux to HDL and not 
lipid-free ApoA-I and thus showed relatively low choles-
terol effl ux to 5A. Reconstituting 5A with either PC or SM 
showed considerably greater effl ux than lipid-free 5A for 
both the ABCG1- and SR-BI-transfected cell lines. At the 
highest concentration tested, both rHDL particles made 
with either SM or POPC were 40–50% more effective cho-
lesterol acceptors from ABCG1- and SR-BI-transfected cells. 
Similar results, however, were also obtained from the mock-
transfected cells, which primarily effl ux cholesterol by a 
passive diffusion process ( 31 ), suggesting that the increase 
in cholesterol effl ux to rHDL was largely due to an increase 
by aqueous diffusion pathway. Although 5A-SM-HDL ap-
peared to have slightly better in vitro effl ux capacity than 
5A-POPC-HDL for all four cell lines tested; overall, the two 
rHDL preparations yielded similar results, regardless of 
the mechanism for cholesterol effl ux from cells. 
 HDL remodeling in plasma 
 To assess how rHDL interacts with endogenous lipopro-
tein, 5A-POPC and 5A-SM were incubated with human 
plasma and HDL remodeling was visualized by 1D and 2D 
native page electrophoresis. Samples of 5A-SM and 5A-
POPC were incubated for 30 min in human plasma at fi nal 
peptide concentrations of 0.5, 0.1, and 0.05 mg/ml. The 
HDL subfractions were separated by size by 1D native page 
electrophoresis ( Fig. 3 ). The incubation resulted in a mea-
surable increase in the pre  HDL band at 0.1 mg/ml con-
centration for 5A-SM and for both rHDL compositions 
at 0.5 mg/ml concentration. The increase in pre  HDL 
a slightly higher percentage of unbound 5A relative to the 
SM-HDL preparation. The HDL peak width appeared to be 
narrower for 5A-SM compared with 5A-POPC, indicating de-
creased polydispersity of the SM-rHDL particles. Both prepa-
rations appeared to be homogeneous in size, as determined 
by DLS measurement. The volume averaged size distribution 
and width of distribution were 12.8 and 2.4 nm for POPC-
rHDL and 9.6 and 0.7 nm for SM-rHDL. The binding of pep-
tide to PLs was also confi rmed by increased helicity of 5A in 
rHDL particles relative to free peptide by circular dichroism 
measurement. The   -helix content of lipid-bound 5A was 
37.9 ± 0.7% and 37.6 ± 0.4% for POPC and SM rHDL, respec-
tively, versus 18.8 ± 0.3% for the free 5A peptide solution 
(n = 3, mean ± SD). 
 The morphology of rHDL particles was observed by 
TEM with negative staining ( Fig. 1 ). Formation of highly 
homogeneous discoidal shaped rHDL of 8–12 nm diam-
eter was observed for 5A-SM. The 5A-POPC rHDL had 
slightly larger size, greater heterogeneity, and a less de-
fi ned shape. Some of these differences could be indica-
tive of lower glass transition temperature of POPC relative 
to SM. 
 The effect of rHDL composition on cholesterol 
effl ux in vitro 
 The effect of the PL composition of rHDL on in vitro 
cholesterol effl ux via ABCA1 ( Fig. 2A ), ABCG1 ( Fig. 2B ), 
and SR-BI ( Fig. 2C ) was examined using BHK cells stably 
transfected with various human transporters that promote 
cholesterol effl ux. The cells were loaded with radioactive 
cholesterol and percent cholesterol effl ux was determined 
following incubation with different concentrations of 5A-
POPC, 5A-SM, and lipid-free 5A peptide. The ABCA1 
transporter is known to primarily promote the cholesterol 
effl ux to lipid-poor or lipid-free ApoA-I and thus was able 
 Fig. 1. Electron microscopy images of 5A-SM (A) and 5A-POPC (B), and particle size distribution analyzed by DLS for 5A-SM (C) and 
5A-POPC (D). The scale bar corresponds to 0.1   m. 
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was observed for both 5A-POPC and 5A-SM; however, the 
effect is more prominent for 5A-SM than for 5A-POPC. 
Similar notable increases in   -1 and   -2 HDL intensities 
were observed for both rHDL preparations. The incuba-
tion of 5A-SM and 5A-POPC with rat plasma also showed 
complete disappearance of   -HDL spots and appearance 
of prominent pre  HDL. These fi ndings suggest that both 
5A-POPC and 5A-SM can readily interact with native HDL 
to induce remodeling in plasma. The HDL remodeling 
was somewhat more prominent upon 5A-SM incubation 
compared with 5A-POPC, which correlates well with 
higher anti-atherosclerotic activity in vivo of 5A-SM, shown 
later in this work. 
 Anti-infl ammatory properties 
 The effects of PL composition on the anti-infl ammatory 
properties of rHDL were examined in two separate ex-
periments. First, mouse peritoneal macrophages were 
harvested, plated, and preincubated with 5A-SM or 5A-
POPC at 0.01, 0.1, and 1 mg/ml concentrations for 18 h. 
Following incubation, the medium was replaced with 
fresh medium without rHDL, and cytokine release was 
stimulated by addition of LPS. Both lipid formulations of 
rHDL exhibited dose-dependent inhibition of cytokine 
release, although 5A-SM appeared to be signifi cantly 
more potent than 5A-POPC ( Fig. 5A ). Both the high 
(1 mg/ml) and mid dose (0.1 mg/ml) of 5A-SM almost 
completely inhibited TNF-  release, while only the 1 mg/ml 
dose of 5A-POPC showed some protection. It is known 
that HDL can physically bind and neutralize LPS; how-
ever, this protection mechanism is unlikely to be appli-
cable here, because the rHDL-containing medium was 
removed and a new medium was added prior to LPS 
stimulation. 
 The ability of 5A-SM- and 5A-POPC-HDL to inhibit cyto-
kine release in whole human blood stimulated by addi-
tion of PHA was also examined. The 5A-POPC and 5A-SM 
was statistically higher for 5A-SM relative to 5A-POPC at 
0.5 mg/ml ( P < 0.05). The 2D gel analysis of 5A-POPC 
and 5A-SM incubations at the highest concentration of 
0.5 mg/ml confi rmed the 1D gel fi ndings ( Fig. 4B ). An in-
crease in pre  HDL (highlighted by dashed circles in  Fig. 4 ) 
 Fig. 2. Concentration dependence of cholesterol 
effl ux by 5A-SM (solid line), 5A-POPC (dashed line), 
and 5A peptide (dotted line). Percent of cholesterol 
effl ux was determined after 18 h incubation of plasma 
with BHK cells stably transfected with ABCA1 (A), 
ABCG1 (B), SR-BI transporters (C), or mock cells 
(D). Statistically signifi cant differences between 5A-
SM and 5A-POPC (*) with  P values of at least <0.05. 
 Fig. 3. Human plasma incubation of 5A-POPC and 5A-SM causes 
HDL remodeling. A: Dose dependent formation of smaller pre  -
like HDL (arrow) upon 5A-POPC and 5A-SM incubation with 
plasma at 0.05, 1, and 0.5 mg/ml relative to PBS control. B: Quan-
titative analysis of pre  HDL formation in each lane. Statistically 
signifi cant increase in pre  HDL was observed for incubation with 
0.5 mg/ml of both rHDL relative to control (* P < 0.05). More pre  
is formed following incubation with 5A-SM relative to 5A-POPC 
(** P < 0.05) 
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unesterifi ed. Statistically signifi cant differences in FC in-
crease between 5A-POPC and 5A-SM were observed for 30 
and 100 mg/kg doses at almost all time points ( P < 0.05, 
noted in  Fig. 6 ). Chromatographic separation of plasma 
lipoproteins 30 min following rHDL dosing revealed the 
presence of mobilized cholesterol in its entirety in the 
HDL fraction, as shown in  Fig. 7 . The analysis confi rmed 
higher levels of mobilized cholesterol in the HDL fraction 
for the 5A-SM infusion relative to 5A-POPC. Approxi-
mately two to three times more cholesterol accumulated 
in the plasma compartment per dose of injected 5A-SM-
HDL relative to 5A-POPC-HDL. The maximum FC mobili-
zation was obtained 3 h postdose for 100 mg/kg, and when 
FC levels increased from baseline by 105.6 mg/dl for 5A-
SM-HDL and by 53.3 mg/dl for 5A-POPC-HDL ( P < 0.01 
for two rHDLs). The baseline level of plasma FC was 30 ± 
5 mg/dl, thus the 30 and 100 mg/kg infusions of 5A-SM 
corresponded to 107 and 387% increases for plasma FC 
levels, respectively. The same doses of 5A-POPC resulted 
in 53 and 189% increases for plasma FC, respectively. 
 The administration of 30 and 100 mg/kg doses of rHDL 
(based on 5A peptide amount) corresponded to infusion 
of 37.5 and 125 mg/kg of either POPC or SM, resulting in 
a signifi cant increase in total circulated plasma PL levels. 
The level of rat plasma PL prior to infusion was approxi-
mately 100–125 mg/ml. The administration of rHDL re-
sulted in initial PL increase by approximately 70–80 mg/ml 
and 400–440 mg/ml for 30 and 100 mg/kg doses, re-
spectively. The initial PL increase was similar for both 5A-
SM and 5A-POPC. While for the 5A-POPC infusion the PL 
lipid levels decreased according to fi rst-order elimination; 
particles were added at 0, 0.01, and 0.1 mg/ml and prein-
cubated for 1 h. Cytokine release was stimulated with PHA 
and the levels of IL-1  , IL-6, and TNF-  were determined 
( Fig. 5B ). Similar to the mouse macrophage results, both 
rHDLs exhibited dose-dependent inhibition of cytokine 
release relative to buffer control ( P < 0.005 for 5A-SM and 
 P < 0.05 for 5A-POPC), and once again 5A-SM offered bet-
ter protection relative to 5A-POPC ( P < 0.01). 
 Cholesterol mobilization and esterifi cation in vivo 
 A rat dose-response study was performed in order to 
evaluate whether apparent differences between 5A-SM- 
and 5A-POPC-HDL in cholesterol effl ux in vitro translate 
to signifi cant differences in cholesterol mobilization in vivo. 
Sprague-Dawley rats received 30 and 100 mg/kg doses 
of 5A-POPC- or 5A-SM-HDL by intravenous infusion. The 
dose was based on the peptide content of the dosing 
solutions. The increase in plasma FC, CE, and PL levels is 
plotted in  Fig. 6A–F . The amount of mobilized FC was 
proportional to the injected dose and reached a maxi-
mum within 1 to 3 h post infusion, depending on the 
dose. Most of the mobilized cholesterol appeared to be 
 Fig. 4. The 2D gel electrophoresis of rat (A) and human (B) 
plasma incubated with either PBS control or 0.5 mg/ml of 5A-
POPC or 5A-SM. Pre  HDL is highlighted by a dashed line circle. 
C: Map of various subclasses of HDL according to classifi cation by 
Asztalos, Tani, and Schaefer ( 30 ). 
 Fig. 5. Inhibition of cytokine release by 5A-POPC and 5A-SM in-
cubation. A: TNF-  release from murine macrophages stimulated 
by addition of LPS was inhibited by preincubation with 5A-SM at 1 
and 0.1 mg/ml and partially inhibited by 5A-POPC at 1 mg/ml . B: 
Inhibition of cytokine release in whole human blood following 
PHA stimulation by addition of 0.1 mg/ml of 5A-POPC (white 
bars) and 5A-SM (solid bars) relative to saline control (lined bars). 
Statistically signifi cant differences between rHDL and PBS control 
(*) and between 5A-SM and 5A-POPC (**) with  P values of at least 
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SM, unlike PCs such as POPC, is not a substrate for LCAT, 
and some reports indicate that SM inhibits LCAT activity 
( 6 ). The increase in CE was plotted at each time point fol-
lowing the infusion for each dose of 5A-SM- and 5A-POPC-
HDL, as shown in  Fig. 6C, D . The dose-dependent increase 
in CE formation was observed for both 5A-SM and 5A-
POPC; however, the absolute amount of CE increase was 
lower than for FC, indicating that only a small fraction of 
mobilized FC converts to CE for both HDL compositions. 
There were no statistically signifi cant differences in CE in-
crease between 5A-POPC and 5A-SM. The CE increase was 
similar for the 100 mg/kg dose of 5A-POPC and 5A-SM, as 
well as 30 mg/kg 5A-SM. These results indicate that rapid 
mobilization of a large amount of FC likely saturates the 
endogenous LCAT esterifi cation capacity. 
 Effect of 5A-POPC and 5A-SM rHDL on atherosclerosis 
regression in mice 
 The ability of rHDL to reduce the atherosclerotic bur-
den was evaluated for both 5A-POPC and 5A-SM rHDL in 
ApoE   /   mice. ApoE   /   mice were placed on high-fat diet 
to develop atherosclerosis (seven to eight animals per 
group). The baseline control group was euthanized prior 
to the start of treatment, while the other three groups re-
ceived intraperitoneal injections of 50 mg/kg 5A-SM, 5A-
POPC, or an equivalent volume of PBS administered three 
times weekly for 6 weeks. Following the conclusion of 
treatment regimens, animals were euthanized and whole 
aortas were excised for plaque area analysis by oil red O 
staining ( Fig. 8 ). The baseline en face atheroma area was 
22.5% and it increased slightly over the treatment period 
for the placebo group to 24.1% ( Fig. 8A, B ). In contrast, 
the atheroma area was reduced to 20.4% and 16.4% fol-
lowing the treatment with 5A-POPC and 5A-SM, respec-
tively. The relative percent reductions of atheroma area by 
5A-SM and 5A-POPC were 28 and 10% compared with 
baseline. There were no statistically signifi cant differences 
between 5A-SM and 5A-POPC groups, likely due to the 
small number of animals and the short duration of treat-
ment. The plaque reduction was statistically signifi cant for 
5A-SM-rHDL relative to PBS with  P < 0.01. Similar results 
were obtained for aortic root lesions ( Fig. 8C, D ). The ath-
eroma area following placebo treatment was 30.0% and it 
was reduced to 24.0 and 20.7% following 5A-POPC and 
5A-SM treatment, respectively. The aortic root lesion re-
duction was statistically signifi cant for 5A-SM treatment 
relative to PBS ( P < 0.05). These results suggest that the PL 
composition of rHDL does indeed affect both cholesterol 
mobilization in vivo and the anti-atherosclerotic potency 
of rHDL in the ApoE   /   murine model. 
 DISCUSSION 
 The most important fi nding of this study is the manner 
and extent to which alteration of rHDL PL composition 
can alter the biological properties of rHDL, in regard to its 
cholesterol effl ux ability and anti-infl ammatory effect. We 
found that 5A-SM effl uxes more cholesterol by SR-BI and 
ABCG1 mechanisms relatively to 5A-POPC, and this ability 
whereas for 5A-SM, a small additional increase in circulat-
ing PL was observed for the fi rst 2–6 h depending on the 
dose. The differences in PL levels were statistically signifi -
cant for 5A-SM and 5A-POPC for the 100 mg/kg dose 2–8 h 
post administration ( P < 0.05). Overall, the circulating PL 
levels remained elevated for a longer duration for 5A-SM 
administration relative to 5A-POPC, most likely due to 
slower metabolism of SM relative to POPC. This slower PL 
elimination correlates with longer circulation of mobi-
lized FC ( Fig. 6A, B ). It is important to note that the 
plasma PL levels return to predose levels 24 h post admin-
istration for both rHDL compositions. 
 Cholesterol mobilization is the fi rst important step in 
the reverse cholesterol transport pathway; however, it is 
important to note that the lipid composition of the rHDL 
particles also affected cholesterol esterifi cation by LCAT, 
the second step in reverse cholesterol transport ( 11, 31 ). 
 Fig. 6. Dose response of cholesterol mobilization following 
5A-POPC and 5A-SM infusions at 30 mg/kg (dashed line ) and 
100 mg/kg (solid line) in normal rats. Unesterifi ed cholesterol or 
FC mobilization by 5A-POPC (A) and 5A-SM (B). Increase in CE 
levels after infusion of 5A-POPC (C) and 5A-SM (D). Increase in 
PLs after infusion of 5A-POPC (E) or 5A-SM (F). *Denotes statisti-
cally signifi cant differences between 5A-POPC and 5A-SM of the 
same dose with  P values of at least <0.05. 
 Fig. 7. Infusion of 5A-POPC (dotted line) and 5A-SM (dashed 
line) leads to rapid cholesterol mobilization in the HDL subfrac-
tion 30 min postdose relative to baseline (solid line). Lipoproteins 
were separated by gel fi ltration chromatography and cholesterol 
levels were analyzed post fraction collection. Peaks at 12, 14, and 
18 min represent VLDL, LDL, and HDL, respectively. 
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of either 100 mg/kg of 5A-POPC or 30 mg/kg of 5A-SM, 
roughly the same percent of FC was converted to CE. All 
mobilized cholesterol was successfully eliminated by 24 h 
post rHDL infusion, even after administration of 5A-SM at 
100 mg/ml, as lipoprotein parameters returned to a base-
line levels. This indicates that rHDL-mobilized cholesterol 
is most likely eventually eliminated by the liver, either as 
CE or as unesterifi ed cholesterol. A control experiment to 
explore cholesterol effl ux in vitro and cholesterol mobili-
zation in vivo following administration of POPC or SM ve-
hicles, without addition of ApoA-I mimetic peptide, was 
not performed in the current study. The administration 
of lipid vehicles results in cholesterol mobilization and en-
dothelial function modulation, and the relative effi cacy 
depends on the size and lamellar properties of the admin-
istered lipid vehicles ( 32, 33 ). 
 The anti-infl ammatory properties of rHDL are also af-
fected by lipid composition; 5A-SM was found to inhibit 
cytokine release in response to LPS more effectively than 
5A-POPC. The anti-infl ammatory activity differences be-
tween 5A-SM and 5A-POPC could be potentially related to 
the differences in alteration of cellular membrane compo-
sition by either passive or SR-BI-mediated effl ux. The SR-
BI-mediated effl ux from the endothelial cells is known to 
cause activation of eNOS by kinase signaling ( 34 ). It is also 
possible that some of anti- and pro-infl ammatory activity of 
is translated to greater cholesterol effl ux capacity by plasma 
following infusion of rHDLs. ABCA1 efflux was not as 
much affected by lipid composition, as it is largely driven 
by lipid-free ApoA-I or the ApoA-I peptide component 
of HDL. The cholesterol effl ux following addition of 5A-
POPC and 5A-SM rHDLs to human and rat plasma re-
sulted in lipoprotein remodeling with notable formation 
of pre  HDL particles. The relative percent of formed 
pre  HDL was higher for 5A-SM relative to 5A-POPC. The 
difference between cholesterol effl ux ability by ABCG1 
and SR-BI for the two rHDL lipid formulations was trans-
lated into a notable difference in FC effl ux in vivo. The 
5A-SM-HDL mobilized roughly twice the amount of cho-
lesterol relative to 5A-POPC-HDL at the same doses ( Fig. 
6 ). The mobilized cholesterol was found in the HDL frac-
tion following chromatographic separation of VLDL, LDL, 
and HDL of a rat plasma sample 30 min post rHDL infu-
sions ( Fig. 7 ). The absolute value of CE increase was simi-
lar for both rHDL compositions at high doses, indicating 
that availability of the endogenous LCAT might be a limit-
ing factor for FC conversion to CE. The conversion of FC 
to CE following administration of SM-based rHDL was 
surprising because SM is not a substrate for LCAT, indicating 
that endogenous PC species are likely to incorporate into 
SM-based rHDL during remodeling in vivo. Indeed, at 
the same level of cholesterol mobilization after dosing 
 Fig. 8. Effect of 5A-POPC and 5A-SM rHDL on atherosclerosis regression in ApoE   /   mice. Aortas were 
dissected and plaque areas were visualized by oil red O staining. Representative lesion images and corre-
sponding quantitative analyses of the aortas (A, B) and the aortic root cross-sections (C, D). N = 7–8 animals 
per group. (*) Denotes statistically signifi cant differences with  P values of at least <0.05; (**) indicates  P 
values of <0.01. 
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18:0), exhibited lower cholesterol effl ux than HDL from 
POPC and DOPC. This effl ux system examines physical 
uptake of FC from cell membranes similar to the mock ef-
fl ux measurement in this study. The higher uptake by un-
saturated lipids was attributed to the liquid crystalline state 
of unsaturated lipids at 37°C. However, the duration of 
rHDL incubation with cells, cell type, and rHDL concen-
tration in the media were different in all the aforemen-
tioned studies, thus limiting direct comparison. It is 
important to note that commercially available SMs are all 
natural mixtures of lipids purifi ed from different sources. 
Egg yolk SM, which is composed primarily of palmitic acid 
(16:0, over 80%), was used in our study, while bovine brain 
SM (  50% of 18:0 and   20% of 24:1) was used by Marmil-
lot, Patel, and Lakshman ( 8 ) and Davidson et al . ( 7 ). Simi-
lar to PC, the fatty acid chain length and saturation is 
expected to affect the cholesterol binding of the SM bi-
layer and effl ux capacity of SM-based rHDL. 
 An important issue is whether the greater cholesterol 
mobilization effi ciency by SM-based rHDL relative to POPC-
based rHDL will result in anti-atherosclerotic effi cacy at 
lower doses. In this study, we did indeed observe a greater 
anti-atherosclerotic activity of 5A-SM relative to 5A-POPC 
following administration of eighteen doses of 50 mg/kg of 
rHDL. Some of our previous data is also supportive of 
greater activity of SM-containing rHDL relative to POPC-
based rHDL ( 26 ). In two independent studies, 4-month-old 
ApoE   /   mice on a normal chow diet were injected with 
30 mg/kg of:  i ) 5A:POPC-HDL or POPC liposome control; 
and  ii ) 5A-SM-DPPC-HDL or saline control for 13 weeks 
(three times a week) and then analyzed for percentage 
of surface area covered by aortic plaque. The atheroma 
area was smaller following 5A-SM-DPPC-HDL treatment 
(  3.5%) relative to 5A-POPC-HDL treatment (  6%). In-
jections of both rHDLs showed statistically signifi cant im-
provement relative to placebo or POPC liposome controls 
( 26 ). The animal experiment design in the current study 
involved feeding ApoE   /   mice a high-fat diet for 14 weeks 
followed by an acute 6 week treatment. The mean ather-
oma areas were 16.4, 20.4, and 24.1% following 5A-SM-
HDL, 5A-POPC-HDL, and placebo treatments, respectively. 
While the atheroma area was lower following 5A-SM treat-
ment relative to 5A-POPC, the difference was not statis-
tically signifi cant. This lack of a statistically signifi cant 
difference could be attributed to the low number of ani-
mals (seven to eight per group) and the short duration of 
treatment (6 weeks). 
 Another critical question is the importance of effective 
interaction of rHDL with LCAT for successful reduction of 
atheroma. While SM is not a substrate of LCAT, fully satu-
rated PC, such as DPPC, is capable of serving as a substrate 
for LCAT and, like SM, is similar in its strong cholesterol 
binding properties. The unsaturated PCs, such as POPC 
and DLPC, are reported to be more effi cient substrates for 
LCAT, but unsaturation results in weaker cholesterol ef-
fl ux. It may be preferable to investigate the effect of lipid 
composition cholesterol esterifi cation in vivo using either 
full-length ApoA-I or ApoA-I mimetic peptides optimized 
specifi cally for LCAT activation. The results of this study 
rHDL is due to small amounts of signaling lipid impurities 
present in SM and POPC raw materials, such as sphingosine-
1-phosphate, sphingosyl-phosphorylcholine, or LPC, or 
these could be generated after cellular uptake by rHDL. 
These molecules are known to be potent bioactive sig-
naling molecules and could impact on the infl ammatory 
cascade ( 34 ). Another potential mechanism of 5A-POPC- 
and 5A-SM-related anti-infl ammatory activity could be 
mediated by ABCA1 effl ux ( 35 ), and related to induction 
of activating transcription factor 3 (ATF3) transcription 
modulator ( 36 ). The causes for the relative differences 
between 5A-POPC and 5A-SM anti-infl ammatory activi-
ties pertaining to these mechanisms have not yet been 
explored. 
 Similar differences between SM- and PC-based rHDL 
were reported in several past studies. ProApoA-I formu-
lated with POPC showed approximately 10-fold lower FC 
mobilization in the HDL fraction relative to proApoA-I-
SM-HDL, following the infusion into New Zealand White 
rabbits at 15 mg/kg doses ( 24 ). The comparison of in vitro 
cholesterol effl ux by ApoA-I and ApoA-I-Milano formulated 
with either 1,2-dimyristoyl-rac-glycero-3-phosphocholine 
(DMPC) or SM was conducted in Chinese hamster ovary 
cells , J774 macrophages, and BHK cells transfected with 
ABCA1, nonfunctional ABCA1 mutant (W590S), and 
ABCG1 ( 9 ). SM-based rHDL exhibited higher cholesterol 
effl ux than DMPC-based rHDL in all cell systems tested, and 
the difference was most signifi cant in ABCG1-expressing 
cells. The PL composition has less effect on ABCA1-
mediated effl ux, and ApoA-I-Milano-based rHDL was a 
slightly better cholesterol acceptor relative to ApoA-I-based 
rHDL. These findings are consistent with ABCA1 and 
ABCG1 effl ux results in our study, using the 5A mimetic 
peptide. 
 The effects of PC, fatty acid saturation, and addition of 
SM to rHDL on cholesterol effl ux from J774 macrophages 
and esterifi ed cholesterol uptake by HepG2 cells were also 
evaluated by Marmillot, Patel, and Lakshman ( 8 ). In gen-
eral, the highest cholesterol effl ux was observed for more 
saturated lipid-based rHDL, such as fully saturated 1,2-
distearoyl-PC (DSPC, 18:0) and 1,2-dioleoyl PC (DOPC, 18:1, 
mono-unsaturated). The incorporation of egg PC (unsatu-
rated natural mixture), 1,2-dilinoleoyl PC (DLPC, 18:2), 
and 1,2-dilinolenoyl phosphatidylcholine (DLnPC, 18:3) 
caused a signifi cant decrease in effl ux capacity . The addi-
tion of SM increased cholesterol effl ux. The CE uptake by 
HepG2 cells was also higher for rHDL containing more 
saturated lipids (50–100% of DSPC), while less uptake was 
observed for egg yolk PC (mostly unsaturated), DOPC, 
DLPC, and DLnPC. Addition of SM at 40–80% of total 
lipid decreased the CE uptake by rHDL containing unsat-
urated lipids, but not for DSPC-based rHDL. 
 Another study of rHDL lipid composition on choles-
terol effl ux from mouse L-cell fi broblasts was performed 
by Davidson et al. ( 7 ), but gave slightly different results. 
The SM-based rHDL exhibited slightly lower effl ux capac-
ity than unsaturated POPC- and DOPC-based rHDL. The 
rHDL based on saturated PCs, such as DSPC (18:0), DPPC 
(18:0), DMPC (14:0), and 1-palmitoyl-2-stearoyl PC (16:0, 
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sition modulates sphingomyelinase activity and ceramide-induced 
membrane physical alterations.  Biophys. J.  96 :  3210 – 3222 . 
are signifi cant because they shift the focus of rHDL re-
search from a protein or peptide component to an equally 
important PL component. While several rHDL products 
have already been translated to early stage clinical trials, 
the doses required for clinical effi cacy are relatively large 
(40 mg/kg and 45 mg/kg), requiring as much as 5 g of 
protein per infusion ( 4, 5, 15, 16 ). Administration of such 
high doses has been associated with toxicity, which may 
have resulted from various impurities, including cholate 
used in preparation of sHDL particles, oxidized lipids, po-
tentially immunogenic ApoA-I aggregates, bacterial pro-
teins, DNA, and endotoxins from recombinant processing 
during manufacturing of ApoA-I. A high dose of 80 mg/kg 
of CSL-111 also had to be discontinued in a phase 2 study 
due to toxicity ( 5 ). High doses also require the manufac-
ture of large quantities of very pure protein or ApoA-I mi-
metic peptide and rHDL nanoparticles, which is technically 
diffi cult and costly. Hence, the ability to attenuate phar-
macological effi cacy of rHDL by optimization of its PL 
composition could potentially lead to the creation of new 
rHDL therapeutics that are effective at a fraction of the 
currently used clinical doses. 
 The end goal of rHDL infusion therapy is to rapidly re-
move excess cholesterol from arterial plaque and reduce 
the risk of future heart attack and, therefore, the ability of 
rHDL to mimic all functions of natural HDL, i.e., endothe-
lial cell layer penetration, cholesterol effl ux from foam 
cells, anti-infl ammatory and anti-oxidant functions, inter-
action with LCAT for conversion of FC to CE, and trans-
port of mobilized and esterifi ed cholesterol to the liver for 
elimination is highly important. As this study and previ-
ously published literature indicate, all of these functions 
of rHDL are potentially affected by its PL composition. 
Therefore, understanding the mechanism of how lipid 
composition alters effi cacy and safety of rHDL is critical 
for successful clinical translation of this novel class of car-
diovascular drugs.  
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